Denali Therapeutics Announces Publication In 'Science Translational Medicine' Demonstrating The Potential Of The OTV Platform To Achieve Broad Biodistribution Of Antisense Oligonucleotides In The CNS And Skeletal And Cardiac Muscle Following IV Administration
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics (NASDAQ:DNLI) announced the publication of nonclinical data in 'Science Translational Medicine' demonstrating the potential of its Oligonucleotide Transport Vehicle (OTV) platform to achieve broad biodistribution of antisense oligonucleotides (ASOs) in the CNS and skeletal and cardiac muscle following IV administration. This breakthrough could address the challenge of delivering ASOs across the blood-brain barrier (BBB) for the treatment of neurological disorders.
August 14, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Denali Therapeutics' publication in 'Science Translational Medicine' highlights the potential of its OTV platform to deliver ASOs across the BBB, which could revolutionize treatments for neurological disorders. This breakthrough may positively impact DNLI's stock price in the short term.
The publication in a reputable journal like 'Science Translational Medicine' validates Denali's OTV platform, which addresses a significant challenge in the delivery of ASOs for neurological disorders. This breakthrough is likely to attract investor interest and positively impact DNLI's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100